Sotabase

Career

· Research Quality Integration Officer, University of Toronto2024–
· Researcher in Machine Learning Group, University of Toronto

Publications (0)

Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group
Annals of Oncology · 2016
290
cited
Chemokine CXCL13 is overexpressed in the tumour tissue and in the peripheral blood of breast cancer patients
British Journal of Cancer · 2008
131
cited
Capecitabine/irinotecan or capecitabine/oxaliplatin in combination with bevacizumab is effective and safe as first-line therapy for metastatic colorectal cancer: a randomized phase II study of the AIO colorectal study group.
Annals of Oncology · 2013
69
cited
Whole-body hyperthermia (41.8 degrees C) combined with bimonthly oxaliplatin, high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer: a phase II study.
Annals of Oncology · 2002
40
cited
A prospective multicenter phase II study of oral and i.v. vinorelbine plus trastuzumab as first-line therapy in HER2-overexpressing metastatic breast cancer.
Annals of Oncology · 2011
28
cited
Infusion of tumor-contaminated bone marrow for autologous rescue after high-dose therapy leading to long-term remission in a patient with relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia.
Bone Marrow Transplantation · 1995
27
cited
No evidence of significant activity of the multidrug resistance gene product in primary human breast cancer.
Annals of Oncology · 1998
25
cited
P-glycoprotein expression in normal and reactive bone marrows.
British Journal of Cancer · 1993
20
cited
Prognostic factors for 60-day mortality in first-line treatment of metastatic colorectal cancer (mCRC): individual patient analysis of four randomised, controlled trials by the AIO colorectal cancer study group.
Annals of Oncology · 2013
13
cited
41.8 degrees C whole body hyperthermia as an adjunct to chemotherapy induces prolonged T cell activation in patients with various malignant diseases.
Cancer Immunology and Immunotherapy · 2002
7
cited
522PQUALITY OF LIFE (QOL) IN PATIENTS WITH METASTATIC COLORECTAL CANCER (MCRC) RECEIVING MAINTENANCE THERAPY AFTER FIRST-LINE INDUCTIVE TREATMENT: A QOL SUB-ANALYSIS OF THE AIO KRK 0207 PHASE III TRIAL.
Annals of Oncology · 2014
2
cited
Inflammatory Stress Determines the Need for Chemotherapy in Patients with HER2-Positive Esophagogastric Adenocarcinoma Receiving Targeted Therapy and Immunotherapy
Cancer immunology research · 2024
2
cited
Sotabase